Supervivencia en cáncer de mama por subtipo mediante inmunohistoquímica: Un estudio retrospectivo

3Citations
Citations of this article
211Readers
Mendeley users who have this article in their library.

Abstract

Background: Breast cancer subtype classification according to hormone receptors (HR) and human epidermal growth factor receptor 2 (HER2) using immunohistochemistry is the standard practice for therapeutic decision making. Objective: To design future studies information on characteristics and survival of each subtype is essential. Method: We conducted a retrospective study to analyze clinical and pathologic features as well as survival data according to breast cancer immunohistochemistry subtype. Results: There were 211 women with a RH(+)/HER2(–) breast cancer subtype, 53 HR(+)/HER2(+), 16 HER2(+) and 23 HR(–)/HER2(–), with a median overall survival in months of 39 (20.5-62.7), 42 (25.5-65), 42 (13.7-67.7) and 26 (11-78), respectively, for a 3.7 hazard ratio of death (95% Confidence Interval [CI]: 1.3-10.3) for the triple negative group as compared to the HR(+)/HER2(–) group (p = 0.01). Conclusions: HR positive subtypes by immunohistochemistry where most frequent and showed a greater overall survival compared to the triple negative subtype.

Cite

CITATION STYLE

APA

Valle-Solís, A. E., Miranda-Aguirre, A. P., Mora-Pérez, J., Pineda-Juárez, J. A., Gallardo-Valencia, L. E., Santana, L., … Cárdenas-Cárdenas, E. (2019). Supervivencia en cáncer de mama por subtipo mediante inmunohistoquímica: Un estudio retrospectivo. Gaceta Medica de Mexico, 155, S50–S55. https://doi.org/10.24875/GMM.19005133

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free